The mission of the Galveston National Laboratory (GNL) is to conduct basic and applied research designed to improve the prevention, diagnosis and treatment of naturally emerging and purposefully disseminated infectious diseases. The GNL provides BSL4, BSL3 and BSL2 laboratories designed to allow the safe conduct of this work. Our strategic plan is to develop a portfolio of basic research and translational product development activities that will fully occupy the GNL containment spaces, including implementation of strategies for cost recovery for each of our Integrated Service Support Divisions;however, we realize that the exceptional costs of security, utilities and maintenance required for the safe and secure operations will continue to demand supplemental support. The GNL was dedicated on November 11, 2008. As of June, 2010, the entire GNL has been inspected by the CDC and USDA Select Agent Programs and approved for full operations. GNL BSL2 and ABSL3 laboratories are active and moving toward full occupancy;the in vitro BSL3 and BSL3E labs are operational with non-Select Agents, and we will soon begin Select Agent use. We anticipate beginning operations in the BSL4 laboratories in August 2010, initially conducting research on pathogens requiring lower containment and handling BSL4 pathogens by the end of 2010. Plans for routine, emergency and preventive laboratory maintenance are operational, as are weather emergency plans and plans for external evaluation of programs. The GNL is organized around 6 Cores and 7 service divisions (Administration, Facilities Maintenance and Operations, Biosecurity, Environmental Health and Biosafety Regulations and Requirements, Regulatory Compliance, and Integrated Support Services Cores; Aerobiology, Preclinical, Assay Development, Pathology, Insectary, Imaging and Immunology service divisions). Staff training is underway, facilitated by the National Biocontainment Training Center. Two active community advisory groups help to maintain a robust and positive dialogue with local community leaders. The GNL assisted the Texas Department of State Health in response to the 2009 H1N1 epidemic and is building upon that model to formalize state and national emergency response activities.

Public Health Relevance

Scientists at the Galveston National Laboratory (GNL) conduct research on the world's most dangerous infectious diseases using state-of-the-art containment facilities to discover and develop better diagnostic tests, effective treatments and improved vaccines. Basic research and translational studies advance discoveries into useful products to prevent against emerging infectious diseases and bioterrorism threats.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
5UC7AI094660-04
Application #
8675794
Study Section
Special Emphasis Panel (ZAI1-PRJ-M (J1))
Program Officer
Boyd, Nancy G
Project Start
2011-05-31
Project End
2016-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
4
Fiscal Year
2014
Total Cost
$14,000,000
Indirect Cost
$4,387,103
Name
University of Texas Medical Br Galveston
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Thi, Emily P; Lee, Amy C H; Geisbert, Joan B et al. (2016) Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nat Microbiol 1:16142
Satterfield, Benjamin A; Cross, Robert W; Fenton, Karla A et al. (2016) Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets. J Virol 90:6326-43
Agrawal, Anurodh Shankar; Ying, Tianlei; Tao, Xinrong et al. (2016) Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Sci Rep 6:31629
Santos, Rodrigo I; Hermance, Meghan E; Gelman, Benjamin B et al. (2016) Spinal Cord Ventral Horns and Lymphoid Organ Involvement in Powassan Virus Infection in a Mouse Model. Viruses 8:
Cross, Robert W; Mire, Chad E; Branco, Luis M et al. (2016) Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res 133:218-22
Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis 214:S367-S374
Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus. J Infect Dis 214:S263-S267
Cross, Robert W; Mire, Chad E; Borisevich, Viktoriya et al. (2016) The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus. J Infect Dis 214:565-9
Mire, Chad E; Geisbert, Thomas W; Feldmann, Heinz et al. (2016) Ebola virus vaccines - reality or fiction? Expert Rev Vaccines 15:1421-1430
Olsen, Michelle E; Filone, Claire Marie; Rozelle, Dan et al. (2016) Polyamines and Hypusination Are Required for Ebolavirus Gene Expression and Replication. MBio 7:

Showing the most recent 10 out of 52 publications